ALIGOS THERAPEUTICS INC (ALGS) Stock Price, Quote, News and Overview
NASDAQ:ALGS - Nasdaq - US01626L2043 - Common Stock - Currency: USD
ALGS Quote, Performance and Key Statistics
5.36
+0.22 (+4.28%)
The current stock price of ALGS is 5.36 USD. In the past month the price decreased by -50.14%. In the past year, price decreased by -72.58%.
ALGS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.5 | 313.20B | ||
| AMGN | AMGEN INC | 14.02 | 149.41B | ||
| GILD | GILEAD SCIENCES INC | 23.08 | 132.62B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1698 | 126.59B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.88 | 64.26B | ||
| ARGX | ARGENX SE - ADR | 319.7 | 36.31B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.48B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.60B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.85B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 24.51B | ||
| NTRA | NATERA INC | N/A | 20.08B | ||
| BIIB | BIOGEN INC | 7.17 | 17.30B |
Related stock screener links
About ALGS
Company Profile
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The company is headquartered in South San Francisco, California and currently employs 70 full-time employees. The company went IPO on 2020-10-16. The firm discovers and develops therapeutics for metabolic dysfunction associated steatohepatitis (MASH) and viruses with high unmet medical need, such as chronic hepatitis B (CHB) and coronaviruses. Its advanced drug candidate for MASH is ALG-055009, a small molecule thyroid hormone receptor beta (THR-ß) agonist. The company is also progressing oligonucleotide projects for MASH. The company is developing a portfolio of differentiated CHB drug candidates, including a small molecule Capsid Assembly Modulator that results in the production of empty viral capsids (CAM-E) and small molecule inhibitors of the Programmed Cell Death Ligand 1 (PD-1/PD-L1) interaction. Its third area of focus is to develop drug candidates with pan-coronavirus antiviral activity. Its pipeline includes ALG-055009, ALG-000184, ALG-125755, and ALG-097558.
Company Info
ALIGOS THERAPEUTICS INC
One Corporate Dr., 2Nd Floor, 2nd Floor
South San Francisco CALIFORNIA 94080 US
CEO: Lawrence M. Blatt
Employees: 68
Company Website: https://www.aligos.com/
Investor Relations: https://investor.aligos.com/
Phone: 18004666059
ALIGOS THERAPEUTICS INC / ALGS FAQ
What is the stock price of ALIGOS THERAPEUTICS INC today?
The current stock price of ALGS is 5.36 USD. The price increased by 4.28% in the last trading session.
What is the ticker symbol for ALIGOS THERAPEUTICS INC stock?
The exchange symbol of ALIGOS THERAPEUTICS INC is ALGS and it is listed on the Nasdaq exchange.
On which exchange is ALGS stock listed?
ALGS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ALIGOS THERAPEUTICS INC stock?
9 analysts have analysed ALGS and the average price target is 103.7 USD. This implies a price increase of 1834.7% is expected in the next year compared to the current price of 5.36. Check the ALIGOS THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ALIGOS THERAPEUTICS INC worth?
ALIGOS THERAPEUTICS INC (ALGS) has a market capitalization of 32.75M USD. This makes ALGS a Nano Cap stock.
How many employees does ALIGOS THERAPEUTICS INC have?
ALIGOS THERAPEUTICS INC (ALGS) currently has 68 employees.
What are the support and resistance levels for ALIGOS THERAPEUTICS INC (ALGS) stock?
ALIGOS THERAPEUTICS INC (ALGS) has a support level at 4.56. Check the full technical report for a detailed analysis of ALGS support and resistance levels.
Is ALIGOS THERAPEUTICS INC (ALGS) expected to grow?
The Revenue of ALIGOS THERAPEUTICS INC (ALGS) is expected to grow by 603.14% in the next year. Check the estimates tab for more information on the ALGS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ALIGOS THERAPEUTICS INC (ALGS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ALGS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ALGS, evaluating the profitability, health, valuation and growth aspects
- ALIGOS THERAPEUTICS INC (ALGS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ALIGOS THERAPEUTICS INC (ALGS) Sales and EPS estimates to see what analysts future expectations are.
- ALIGOS THERAPEUTICS INC (ALGS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ALIGOS THERAPEUTICS INC (ALGS) Insider and Institutional Ownership to learn about the owners and their transactions.
- ALIGOS THERAPEUTICS INC (ALGS) Stock Chart to make your own analysis
- ALIGOS THERAPEUTICS INC (ALGS) Latest news and press-releases to stay up to date.
Does ALIGOS THERAPEUTICS INC (ALGS) stock pay dividends?
ALGS does not pay a dividend.
When does ALIGOS THERAPEUTICS INC (ALGS) report earnings?
ALIGOS THERAPEUTICS INC (ALGS) will report earnings on 2025-05-05, after the market close.
What is the Price/Earnings (PE) ratio of ALIGOS THERAPEUTICS INC (ALGS)?
ALIGOS THERAPEUTICS INC (ALGS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.17).
What is the Short Interest ratio of ALIGOS THERAPEUTICS INC (ALGS) stock?
The outstanding short interest for ALIGOS THERAPEUTICS INC (ALGS) is 25.35% of its float. Check the ownership tab for more information on the ALGS short interest.
ALGS Technical Analysis
ALGS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALGS. ALGS has a bad profitability rating. Also its financial health evaluation is rather negative.
ALGS Financial Highlights
Over the last trailing twelve months ALGS reported a non-GAAP Earnings per Share(EPS) of -11.17. The EPS increased by 71.9% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -187.19% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ALGS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to ALGS. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 20.92% and a revenue growth 603.14% for ALGS